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Summary  
Allergen immunotherapy (AIT) is aimed at inducing tolerance to allergens, such as pollens, dust mites 
or moulds, by administering increasing amounts of the causative allergen through subcutaneous or 
sublingual route. The evidence of efficacy of AIT is high, but the issue of safety, especially for the 
subcutaneous route, must be taken into account. The search for safer AIT products aimed at reducing 
the allergenicity, and thus adverse reactions, while maintaining the immunogenicity, that is essential 
for effectiveness, gave rise to the introduction of allergoids, which were conceived to fulfill these 
requirements. In the first allergoids glutaraldehyde or formaldehyde were used as cross-linking agent 
to polymerize allergens, this resulting in high molecular weight molecules (200,000 to 20,000,000 
daltons) which were significantly less allergenic due to a decreased capacity to bridge IgE on its 
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specific receptor, while maintaining the immunogenicity and thus the therapeutic efficacy. In recent 
years further agents, acting as adjuvants, such as L-tyrosine, monophosphoryl lipid A, aluminium 
hydroxide, were added to polymerized extracts. Moreover, a carbamylated monomeric allergoid was 
developed and, once adsorbed on calcium phosphate matrix, used by subcutaneous route. At the same 
time, in virtue of its peculiarities, such allergoid revealed particularly suitable for sublingual 
administration. A lot of clinical evidences show that it is well tolerated, largely safer and effective. 
Importantly, the higher safety of allergoids allows faster treatment schedules that favor patient 
compliance and, according to pharmaco-economic studies, they might be more cost-effective than 
other AIT options. 
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Background   
Allergen immunotherapy (AIT) was introduced in 1911 by Noon and Freeman, with the provisional 
name of "desensitizing vaccine"[1]. This treatment was aimed at reducing the reactivity to allergens, 
namely grass pollen, by subcutaneous administration of increasing amounts of the causative allergen, 
but remained for decades merely empirical. The discovery of IgE antibodies in the 1960s [2] was 
crucial for the development of scientific knowledge on the mechanism of allergy, leading to a marked 
improvement in the diagnosis but also in the quality of allergen extracts for AIT [3). The introduction 
in the 1980s of immunotherapy products of high biological potency was a further step towards the 
quality improvement and the consequent reliability of AIT, but the issue of safety came to light. 
Reports of fatal reactions to subcutaneous immunotherapy from the UK [4] and the USA [5] were 
published, inducing to reappraise, especially in patients with allergic rhinitis, the feasibility of a 
treatment burdened by the risk of severe adverse reactions. Such an issue motivated the search for 
safer AIT products, intending to reduce the allergenicity, and thus adverse reactions while 
M
an
us
cr
ip
t a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n
maintaining the immunogenicity that is essential to induce the immunological modification 
associated with effective AIT. The first approach to reach this goal was accomplished by introducing 
the allergoids, conceived to fulfill such the requirements, then followed by a dose reduction in co-
administration of the allergen dosage concomitant to adjuvants, and by routes of administration 
different from the injective route. 
 The evolution of allergoids for subcutaneous immunotherapy                                        
The first study on allergoids obtained by polymerization of allergens using glutaraldehyde as a cross-
linking agent dates back to 1973 [6]. Such chemical treatment resulted in high molecular weight 
molecules (200,000 to 20,000,000 daltons) which were significantly less allergenic due to a decreased 
capacity to bridge IgE on its specific receptor while maintaining the immunogenicity and thus the 
therapeutic efficacy. After 10 years of studies, Grammer et al. concluded that this approach was the 
most successful in providing a good balance of safety, efficacy and, and immunogenicity in multiple 
clinical trials [7]. In Europe, the allergoids obtained by the treatment of the partially purified pollen 
extracts with formaldehyde were evaluated. In 1982 Puttonen et al. showed that the formaldehyde 
treatment resulted in a change of the net charge of proteins to the more acidic site, in a considerable 
reduction of the activities of naturally occurring enzymes of native allergen extracts, and the 
observation of only a trace of activity in the RAST inhibition assay [8]. In the study by Bousquet et 
al. a lyophilized extract of grass pollen was dissolved in a phosphate buffer, adding formaldehyde to 
the solution to obtain a 10 mg/ml pollen extract. After incubation, the solution was dialyzed at +4” C 
to remove formaldehyde and lyophilized. The product was administered by a rush schedule and 
compared to SCIT with a common standardized grass extract. Both treatments were effective on grass 
induced rhinitis, more severe reactions were observed with the standardized extract, but also patients 
treated with the allergoid had SRs [9]. The reduction but not abolition of SRs was also confirmed 
with other kinds of allergoids, such as the formalinized alum-absorbed allergoid. In a double-blind, 
placebo-controlled study on patients with grass-pollen allergy high doses of grass allergoid, 
corresponding to a cumulative pre-seasonal dosage of 46,050 protein nitrogen units (PNU), were 
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administered, with only one systemic reaction. All patients were evaluated before and during the 
treatment by symptom-medication scores, specific nasal and skin reactivity, and immunological 
(specific IgE, IgG, IgG1 and IgG4 antibodies) parameters. The actively treated patients had 
significantly lower symptom-medication scores than placebo during the month of May and showed a 
significant decrease in specific skin and nasal reactivity, and a significant early increase in specific 
IgE, IgG, IgG1, and IgG4, with a subsequent decrease of IgE and IgG1 [10]. A similar aluminum 
hydroxide-adsorbed depot allergen preparation produced by allergen modification by formaldehyde 
and titrated in therapeutic units (TU) was studied in a placebo-controlled trial on children with grass 
pollen-induced allergic rhinitis. Children in the immunotherapy group received 7 injections of grass 
pollen allergoid before grass pollen season and remained on maintenance treatment 27 months. 
Clinical and laboratory parameters were compared between the active and placebo-treated groups. 
After 1 year of immunotherapy, the rhino-conjunctivitis symptom-medication score was significantly 
lower in the immunotherapy group, and skin test reactivity and nasal reactivity to grass pollen were 
significantly decreased. Grass-specific IgG, IgG1 and IgG4 increased significantly already at the end 
of the s build-up therapy, while the seasonal increase in IgE was blunted by active treatment [11]. A 
recent double-blind, placebo-controlled trial evaluated the dose-response relationship of the same 
allergoid preparation comparing a single species (Phleum pratense) and a multiple species mixture. 
Three doses of P. pratense allergoid (1800 TU, standard-dose 6000 TU and 18 000 TU) were 
compared with placebo and the marketed 6-grass pollen allergoid (6000 TU). The primary endpoint 
was the change in weal size in response to the intra-cutaneous testing before and after treatment, while 
secondary outcomes were the change in total nasal symptom score measured assessed in the allergen 
exposure chamber, the changes in P. pratense-specific IgG4 and the incidence of adverse events. All 
three doses of the P. pratense and the 6-grass pollen allergoid preparations were significantly superior 
to placebo for the primary endpoint, while no significant differences in the change in nasal scores 
were detected. The high-dose of P. pratense, when compared to the standard-dose, did not yield any 
additional significant benefit, but was associated with a slight increase in adverse reactions [12]. 
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Further allergoid preparations include the addition to polymerization (by glutaraldehyde or 
formaldehyde) of L-tyrosine and monophosphoryl lipid A, aluminum hydroxide. 
 Henmar et al. performed a direct comparison of three intact allergen extracts and four allergoids 
using IgE inhibition and basophil activation assays to measure the allergenicity, the human T cell 
proliferation and specific IgG-titres following mouse immunizations to assess immunogenicity of all 
products. The results showed important differences in both allergenicity and immunogenicity, that 
require specific documentation of clinical safety and efficacy for each product [13]. As far as safety 
is concerned, the Paul-Ehrlich-Institute published a report on adverse drug reactions (ADRs) to 
injective immunotherapy from 1991 to 2000. ADRs to allergoids classified as serious were evaluated 
between 0.01% and 0.0005%, corresponding to one serious ADR in 10,000 to 200,000 injections. 
"Although based only on absolute numbers, the hypothetical assumption regarding better tolerance 
of the allergoids compared to native allergen preparations was not confirmed, while concerning 
delayed ADRs 75% of them were related to unmodified semi-depot preparations, and 25% were 
related to allergoids [14]. In a recent review by Rajakulendran et al. on novel strategies for AIT, which 
analyzed the data from grass pollen allergoids currently available, the pharmaco-economic aspects 
were also considered. Based on the available studies, the authors concluded that allergoids, mainly 
based on their shorter schedules of administration, might be more cost-effective than other AIT 
options [15]. 
The development of allergoids for sublingual immunotherapy     
A particular allergoid to be administered by sublingual route has been developed. and used for almost 
30 years. The product used was a carbamylated monomeric allergoid, which is a chemically modified 
allergen obtained by substitution of ε-aminogroups of allergen lysine residues, which reduces IgE-
binding activity while preserving immunogenicity. Initially this allergoid  was used for subcutaneous 
route [16] once adsorbed into a matrix of calcium phosphate; at the same time the peculiarities 
(monomericity) of this allergoid made it particularly suitable for sublingual administration. The 
definition of monomeric derives from the selectivity of carbamylation, which does not concern the 
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structural conformation, with no increase of the size of the allergen molecule as occurs with 
polymerization. The first double-blind, placebo-controlled trial on the efficacy of an allergoid 
administered by the sublingual route was published into Lancet as a demonstration of its originality. 
In patients with mite-induced rhinitis, active treatment resulting in significantly lower symptom 
scores and a significant decrease of the immune-mediated inflammatory response [17]. The second 
trial evaluated the efficacy of sublingual tablets of monomeric allergoid obtained from grass pollen 
in children with rhinitis and asthma caused by grass pollen. Children receiving a preseasonal active 
treatment had a significant reduction of symptoms scores, particularly bronchial symptoms, and a 
decrease of nasal eosinophil cationic protein, with good tolerance to the allergoid [18]. The safety in 
children was confirmed in subjects aged less than 5 years treated with either mite of grass pollen 
monomeric allergoids [19]. A further safety study evaluated 105 patients (28 children and 77 adults) 
undergoing SLIT with a mite or grass pollen or Parietaria pollen by an ultra-rush schedule reaching 
the top dose in 20 minutes. Only one patient (0.9%) had an adverse reaction consisting of gastric 
pyrosis, with spontaneous recovery [20]. Indeed, several other studies on the efficacy and safety of 
monomeric allergoids are available, which were analyzed in 2010 by Mösges et al., in a systematic 
review and meta-analysis. The global number of patients with allergic rhinitis included in these 
studies were 266 for grass pollen and 241 mite allergoid. The average improvement in symptom 
scores was 34% for grass pollen and 22% for mite allergoid in comparison with the placebo group, 
and the average improvement in medication scores was 49% and 24% for grass pollen and mite 
allergoid, respectively. Few side effects, with no systemic reactions, were reported in the trials [21]. 
The most recent studies investigated the dose-dependence and dose-finding of monomeric allergoids. 
The first study evaluated the efficacy and safety of the dose of 1000 or 2000 allergy units (AU) in 34 
mite allergic patients, using as primary outcome the change of the threshold of allergen concentration 
inducing a positive nasal provocation test. After 12 weeks all patients treated with 1000 AU and all 
but one treated with 2000 AU had an increase in the threshold dose inducing positive provocation 
tests. The rate of adverse reactions, all mild, was comparable with the two doses [22]. In a 
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randomized, double-blind, phase 2 study on 158 adult patients with grass pollen-induced 
rhinoconjunctivitis, four different doses, equal to 300, 600, 1000 and 2000 UA/day were 
administered. The rate of patients with no symptoms to conjunctival provocation test after treatment 
was 54.3, 47.6, 59.0 and 51.4%, respectively, suggesting 1000 UA/day as the optimal dose No serious 
adverse event was reported [23]. However, in a 12-week double-blind, placebo-controlled dose-
finding study on 131 patients with mite-induced rhino-conjunctivitis receiving the dose of 300, 1000, 
2000. Or 3000 UA/day, the highest rate of treatment response, as assessed by the conjunctival 
provocation test, was observed with the 2000 UA/day (88.5%). An overall number of 20 treatment-
related adverse events (all mild) were recorded [24]. The positive clinical outcomes of the 
carbamylated monomeric allergoid are supported by immunological investigations, which disclosed 
that the mechanisms of action are those illustrated for AIT in general. In fact, SLIT with mite 
monomeric allergoid was shown to down-regulate allergen-specific IgE and to increase interferon-
gamma- and interleukin (IL)-10 production, commonly associated with the development of allergen 
tolerance [25]. The up-regulation of IL-10 was detected also during a short-term course (60 days) of 
SLIT with grass monomeric allergoid, along with allergen-specific T-cell proliferation and reduction 
of allergen-specific in vitro proliferation [26]. In a study comparing two induction schedules of SLIT 
with mite monomeric allergoid of different duration (98 days vs. 16 days) the more rapid induction 
scheme was associated with a reduction in TNF-alpha and IL-4 at the end of induction [27]. 
For complete information of the reader, Table 1 summarizes the main results of all the available 
studies on SLIT with carbamylated monomeric allergoid, 
Conclusions                                                                                                               
The introduction of allergoids was an actual advance for AIT with inhalant allergens, providing a 
response to the problem of systemic reactions to injective immunotherapy, which rather commonly 
hindered the performance of the treatment, being rarely able even to result in fatal events. Abundant 
literature supports the role of allergoids in AIT, including for injective AIT several types, obtained 
by different chemical treatments of the natural allergens to reduce allergenicity while maintaining the 
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immunogenicity and thus the therapeutic efficacy. Also, a product to be used by the sublingual route 
is available, which consists of the carbamylated monomeric allergoid, which has good evidence of 
efficacy and safety. Still, there is room for allergoids characterization, taking into account the 
allergoids require more sophisticated analytical methods than native extracts [28]. In addition, in the 
current landscape of the regulatory requests governing allergen products, special requirements need 
to be implemented for control of allergoids [29]. We have identified a total of 24 journal articles 
reporting 313 participants as total number of active patients and 298 participants as total number of 
placebo/control group (Lais Mites: 64 active/ 61 placebo-control ; Lais Birch 55 active /82 placebo-
control; Lais Grass 114 active/ 95 placebo-control; Lais Parietaria 80 active/ 60 placebo-control). 
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Allergen Study Study 
objective 
Study design Scheme  
-Duration- 
Dose 
No patient  Patology Results 
Lais Mites - 
Chemically 
Modified 
Allergen 
Extract of 
house dust 
mites 
(Dermatopha
goides 
pteronyssinu
s 50%, 
Dermatopha
goides 
farinae 50%) 
Pacor ML 
(1995) [30] 
Efficacy 
and safety 
Open observational 
Study  
Continuative –  
2 years- increasing 
doses 25/100/300/1000 
AU alternate days, 
each dose for 3 times; 
maintenance dose: 1 
tablet of 1000 AU 
weekly. 
14/- Asthma 
of light or 
moderate 
degree  
Before and after the treatment: 
• Reduction of the number and severity of asthma attacks (p<0.001)  
• Improving the expiratory peak flow (PEF) (p<0.001). 
• No side effects were observed and all patients concluded the study  
 
Passalacqua 
G (1998) 
[17] 
Efficacy 
and safety  
Randomised, 
placebo controlled, 
double-blind, 
parallel study 
Continuative - 24 
months- increasing 
doses 25/ 50/ 
100/200/300/600/1000 
AU alternate days, 
each dose for 3 times; 
maintenance dose: 2 
tablets of 1000 AU 
twice weekly. 
10 Active / 
9 Placebo 
Perennial 
rhinoconjuncti
vitis, at 
least for 2 
years 
 
Active vs Placebo: 
• Neutrophilic infiltration decreased (p=0·002). 
• Eosinophilic infiltration decreased before challenge (p=0·001).  
• ICAM-1 expression reduced before challenge (p=0·01) and during and after 
treatment (p=0·002) 
• ECP decreased after 12 months of treatment (p=0·04)  
• The treatment was well tolerated. 1 local (oral itching) side-effects in active 
group  
Lombardi 
(2001) [31] 
Safety  Observational 
Study 
Continuative  
– 31.9 months -  
increasing doses 25/ 
50/ 
100/200/300/600/1000 
for 8 weeks every 
other day; maintenance 
dose 2000 AU once a 
week. 
 
69/- Perennial or 
seasonal 
rhinitis and/or 
mild asthma 
• 17 adverse events corresponding to 7.5% of patients and 0.52 per 1000 doses: 7 
episodes of rhinitis, 3 of oral itching, and 1 of abdominal pain. Two cases of 
urticaria and two of abdominal pain/nause were controlled by a temporary dose-
adjustment, and one case of urtìcaria and conjunctivitis required oral antihistamines.  
• Medical intervention was needed in six patients only during a 3-year period. 
• No severe systemic side-effect  
*The events reported as results of Lombardi’s study were observed in 198 patients 
receiving different SLIT treatments (69 patients – Mites ;75 patients – Grasses; 46 – 
Parietaria; 4 Birch; 1 Olive; 3 Compositae) 
Passalacqua 
G (2006) 
[32] 
Efficacy 
and 
Safety 
Randomized, 
placebo-controlled, 
double-blind, 
multicenter 
 
Continuative  
– 2 years - 
Increasing doses 25/ 
50/ 
100/200/300/600/1000 
AU on alternate days, 
each dose for 3 times; 
maintenance dose: 1 
tablet of 1000 AU 
twice weekly. 
34/34  Mild persistent 
rhinitis  
with/without 
mild 
intermittent 
asthma, 
since at least 2 
years 
Active vs Placebo: 
• Fifty-six patients completed the study (28 Active/ 28 Placebo)  
• A significant difference in the clinical score after 1 year of treatment (P = 0.027) 
• A significant difference for the symptom nasal obstruction after 1 year (P=0.05) 
and 2 years (P=0.033) 
• A significant global drug intake at the first year of treatment (P = 0.036)  
• A significant change in SLIT group was seen for the item change in health status 
(P = 0.05) after the second year of treatment. 
• No relevant side effect was reported (30 vs 43 events) 
• The need for extra visits was lower in the active group (25% vs 43%) 
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Allergen Study Study 
objective 
Study design Scheme  
-Duration- 
Dose 
No patient  Patology Results 
Cosmi L  
(2006) [25] 
 
Efficacy  Open, randomized, 
two arm parallel 
group: one treated 
with SLIT, 
one untreated 
(UT) and 
receiving only 
rescue 
symptomatic 
drugs 
Continuative  
- 1 year and half –  
increasing doses (25/ 
50/ 
100/200/300/600/1000 
AU for 8 weeks every 
other day;  
the maintenance dose 
of 1000 AU once a 
week. 
 
12 SLIT-
treated/ 13 
untreated 
(UT) 
Perennial 
rhinitis 
and/or rhinitis 
plus mild 
asthma 
Active vs Control: 
• Twenty patients (80%) completed the study (11 T and 9 UT).  
• A significant reduction of symptom medication scores after 12 and 18 months of 
treatment (P<0.05) 
• Reduction of Dp-specific IgE after 12 and 18 months (P<0.05 and P<0.005 
respectively) of therapy 
• The serum levels of CXCL10 (an IFN-g-driven chemokine) after 12 and 18, but 
not after 6 months, of treatment were significantly higher (P<0.05) 
• IL-10 were significantly increased (P<0.05) in culture supernatants of PBMC 
from 6 month-treated patients in comparison with those detected at the beginning of 
therapy 
Giordano T 
(2006) [33] 
Efficacy 
and safety  
 
Open observational 
study 
Continuative – 1 year-
Four-day build-up :1st 
day 500 AU, 2nd day 
1.000 AU, 3rd day 
1500 AU, 4th day 2000 
AU . Maintenance: 5-
365 day 1000 AU 
twice weekly  
27 moderate/ 
severe rhinitis, 
with or not 
moderate 
asthma, 
perennial or 
seasonal  
• Improvement of the VAS scores was observed.  
• Decrease of the drug consumption {p<0.01).  
• No side effects: Only two mild adverse reactions: somnolence and tiredness 
 
*The study observed 39 patients house-dust mite (n. 27), grass pollen (n. 7), olive 
pollen (n. 3), cat dander (n. 1) and Parietaria pollen (n. 1). 
D'Anneo RW 
(2010) [34] 
 
Efficacy 
and 
Safety 
Prospective, open-
label, randomized 
study included two 
parallel groups one 
treated with SLIT, 
one treated with 
standard pharmaco 
-therapy (control 
group) 
Continuative  
- 12 months – 
300 AU tablet each 
day for 4 day and the 
12-month; 
maintenance dose 2000 
AU/week 
15/15 Intermittent or 
persistent 
rhinitis or rhino 
conjunctivitis 
and/or 
intermittent, 
mild-persistent 
or persistent 
moderate-
severity 
allergic asthma 
SLIT group vs Control:  
• All patients very well tolerated both the four-day build-up phase and the 12-
month maintenance phase   
• Visual Analogue Scale rises significantly, about 45%, in both groups (p=0.001). 
• Reduction in the global symptom score SLIT group vs control group, about 52% 
(p=0.0004). 
• Smaller rescue drug consumption SLIT group vs control group, about 9%. 
• The difference between before SLIT (T0) and after 12 months (Tl) was highly 
significant in skin reactivity (p=0.000003). The control group had a small increase 
in skin-reactivity (2.6±15.7%) with significance between T0 and Tl (p=0.5226). 
Lais 
Betulle- 
Chemically 
modified 
Burastero SE 
(2009) [35] 
Efficacy 
and 
Safety 
Open 
observational, 
parallel 
grouped: active 
and placebo 
Continuative  
- 6 months –  
1,000 AU every day 
11/11 Seasonal 
allergic rhino 
conjunctivitis 
with or not 
mild asthma 
• Two patients had transient itching in their mouth, spontaneously disappeared. 
• During the pollen season symptoms/drug usage scores improved of 30% and 
40% respectively in actively treated and control patients (p<0.0001); well-days 
(days without intake of rescue medications and symptoms score less than 2) were in 
33% and 23% of patients respectively (p=0.0024). 
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Allergen Study Study 
objective 
Study design Scheme  
-Duration- 
Dose 
No patient  Patology Results 
allergen 
extract of 
trees 
pollens 
(Betula 
pendula 
50%, 
Alnus 
incana 
50%) 
L. 
Bommarito 
(2009) [36] 
Efficacy  Open, randomized, 
parallel group: 
three active 
groups 
Continuative  
-18 months-  
pre-coseasonal 
regimen (T1) (6,000 
AU/week for 10 
weeks/year for two 
years); perennial 
regimen (T2) (2,000 
AU/week for the entire 
study period) 
8 T1+ 8 T2 
/5 T3 
(Drug 
Therapy 
alone) 
Allergic 
rhinoconjuncti
vitis 
with/without 
mild 
intermittent 
asthma 
• T1 vs T2: significant improvement of both nasal obstruction (p<0.01) and other 
symptoms (p<0.01).  
• Significant reduction of antihistamine consumption as well as rescue medication 
score in T1 vs T3 patients (p<0.05).  
• T2 vs T3 patients reported less nasal congestion and ocular symptoms in 2008 
season (p< 0.01).  
• No significant AR have been observed. 
Passali D 
(2010) [37] 
Efficacy 
and 
Safety 
Prospective, 
open, randomized 
study, with three 
parallel groups and 
control group 
Continuative  
-6 months -  
1,000 AU (Group A);  
500/1,000/1500 AU 
up-dosing in 4-day 
(Group B); 
300/600/900/1200 AU 
(Group C) up-dosing 
in 4-day;  
Maintenance: 1,000 
AU 5-7 times a week  
4 (Group 
A) / 3 
(Group B) / 
3 (Group 
C) / 3 
(control) 
Rhinitis and 
oculo-rhinitis 
Treated VS Control 
• All patients tolerated all the three dosage very well, no patient interrupted 
• A statistically significant (p < 0.02) reduction of SMSs vs control group 
• Significant (p < 0.01) decrease in nasal reactivity the three SLI T-treated groups, 
while the untreated controls remained unchanged 
• A significant increase in VAS values has been observed in all 3 study groups, in 
comparison to the controls (p < 0.001). 
• During up-dosing 4 slight side-effects in 4 patients, 1 somnolence and 1 
tiredness, and 2 oral itching. No side-effects were recorded during the maintenance 
treatment. 
Marogna M 
(2013) [38] 
Efficacy 
and 
Safety  
Open 
randomized 
parallel 4 
groups study: 
Group 1: BUD 400 
mcg/day + anti Lt/s  
Group 2: BUD 800 
mcg/day 
Group 3: BUD 
1600 mcg/day 
Group 4 : BUD 
400 mcg/day + 
SLIT 
Discontinuos - 3 
seasons of treatment 
(February to April) –  
four-day 
build-up phase 
followed by a 
maintenance phase of 
three years (1000 
Allergic Unit once a 
day for five 
days/week)  
Group 1 
(n=21) / 
Group 2 
(n=21) / 
Group 3 
(n=21) / 
Group 4 
(n=21) 
Seasonal mild 
and persistent 
asthma and 
normal lung 
function 
associated with 
AR 
• A significantly performance associated with the use of SLIT; only patients of 
group 4, achieved an appreciable control (mean 24; SEM 0.242).  
• A significant improvement in allergy symptoms-medications scores (SMS),  
in patients of group 4 (decrease of 87%) than in all other groups (p < 0.01). 
• The FEV1 increase and the albuterol intake in group 4 was significantly lower 
after three years (p < 0.001),  
• Reduction of nasal eosinophils and nasal corticosteroids in group 4 
• Significant difference in the PD20 was detected at baseline between the controls 
and the 1,000 AU and between the 1,000 and 2,000 AU groups 
• During the three years of SLIT course, two patients reported one episode of  
occurred during the maintenance phase and self-resolved without any therapy in less 
than two hours. 
Lais 
Grasses- 
Chemically 
modified 
allergen 
Bordignon V 
(1994) [39] 
Efficacy Randomised, 
placebo-controlled, 
double-blind 
parallel study 
Discontinuos – 3 
seasons of treatment 
(February to April) – 
25/100/300 and 1,000 
AU every other day (3 
times a week) 
30/30 Perennial rhino 
conjunctivitis 
and/or asthma 
at least for 2 
years 
Active vs Placebo: 
• A statistically significant reduction of nasal and bronchial symptoms particularly 
after the second and the third years of treatments (p < 0.01).  
• Significant reduction of drugs consumption (p < 0.01) 
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extract of 
grass 
pollens 
(Holcus 
lanatus 
33%, 
Phleum 
pratense 
33%, Poa 
pratensis 
33%) 
Pacor M.L. 
(1996) [40] 
 
Efficacy Open non 
comparative 
Discontinuos – 6 pre-
seasonal months for 2 
years- increasing doses 
25/100/300 up to 1,000 
AU every other day (3 
times a week) 
34 Seasonal rhino 
conjunctivitis 
• After 1 years, reduction of symptoms: sneezing (p<0.001), nasal itching 
(p<0.001) and ocular symptoms (p<0.001) and improvement at the second year 
• Significant reduction of antihistamine consumption (p<0.001) 
• Treatment well tolerated and no side effects 
Caffarelli C. 
(2000) [18] 
Efficacy 
and safety 
Randomised, 
double-blind, 
placebo-controlled 
study 
Continuative-  
3 months before pollen 
season- increasing 
doses 
25/50/100/200/300/600 
and 1,000 AU 
every other day (3 
times a week) 
24 active / 
24 placebo 
Seasonal 
rhinitis and/ or 
rhino- 
conjunctivitis 
and/or 
bronchial 
asthma 
Active vs Placebo: 
• 44 out of 48 patients (91.6%), all 24 in the active treatment group and 20 of 24 
given placebo, completed the study: three because they moved away, and one 
because of a mild side-effect (abdominal pain) 
• Significant reduction of total symptoms (P<0.05) during the pollen season 
• Treatment well tolerated and compliance was good 
• EG2/EGl increased significantly only in the placebo group during natural 
allergen exposure (P< 0.01) 
Lombardi C 
(2001) [41] 
Efficacy 
and safety  
Open, controlled 
study 
Discontinuos – 3 
months of 
pre-seasonal 
treatment for 
3 years (1995- 
1997) - cumulative 
dosage, 
36,000 AU 
 
26 
(pharmaco-
therapy + 
SLIT) / 
25 
(pharmaco- 
therapy 
only) 
Seasonal 
rhinoconjuncti
vitis 
and/or asthma 
(mild 
intermittent or 
mild persistent) 
Active vs Control: 
• Significant increase (p=.0.01) of PD20 at the methacholine 
• Significant clinical improvement both for rhinitis (p = 0.001) and asthma 
(p=0.001) 
• Reduction of drug intake (p= 0.001)  
• Improvement of rhinitis symptom without modification of drug intake  
• Treatment well tolerated and no relevant side effects during the 3 years. 
Lombardi C 
(2001) [31] 
 
Safety  Observational 
Study 
Continuative  
– 9.2 months -  
increasing doses 25, 
50, 100, 200, 300, 600, 
1000 for 8 weeks every 
other day; maintenance 
dose 2,000 AU once a 
week. 
 
75/- Perennial or 
seasonal 
rhinitis and/or 
mild asthma 
• 17 adverse events corresponding to 7.5% of patients and 0.52 per 1000 doses: 7 
episodes of rhinitis, 3 of oral itching, and 1 of abdominal pain. Two cases of 
urticaria and two of abdominal pain/nause were controlled by a temporary dose-
adjustment, and one case of urtìcaria and conjunctivitis required oral antihistamines.  
• Medical intervention was needed in six patients only during a 3-year period. 
• No severe systemic side-effect  
*The events reported as results of Lombardi’s study were observed in 198 patients 
receiving different SLIT treatments (69 patients – Mites ;75 patients – Grasses; 46 – 
Parietaria; 4 Birch; 1 Olive; 3 Compositae) 
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Quercia O 
(2001) [42] 
 
Efficacy 
and safety  
Prospective, 
randomized, 
open controlled 
trial with three 
parallel groups. 
Continuative for 16 
days: 25/100/300/1000 
AU.  
After for 2 years: 
Continuative Group 1 
1,000 AU/week -  
Pre-seasonal Group 2: 
5,000 AU/week for 10 
weeks/year, on demand 
drug therapy alone 
(Group 3) for 2 years 
Group 1 
(n=10), 
Group 2 
(n=11) 
and Group 
3 (n=11). 
Rhino-
conjunctivitis 
with/without 
mild 
intermittent 
asthma 
• Significant VAS improvement in both SLIT groups, after the first and second 
pollen season, compared to baseline and to Group 3(p<0.05).  
• Less symptoms and need for medications resulted during the second season 
(p<0.05).  
• Lower drug assumption was significantly in both SLIT groups during the second 
season (p<0.05) 
• Lower global symptoms score in comparison Group 1 and Group 2 vs Group 3 
during the second pollen season (p<0.05) 
• Treatment well tolerated, only 2 patients reported local or mild adverse events 
and one of this has interrupted the study (Group 1 - originally 11). 
A.G. Palma 
Carlos 
(2006) [43] 
Efficacy 
and safety  
Monocentric 
randomised,  
double-blind, 
placebo controlled 
Discontinuos -  pre-
seasonal months for 2 
years - 25, 100, 300 
and 1,000 AU every 
other day (3 times a 
week) for 14 weeks 
1,000 AU 2 times a 
week till May. 
17 Active / 
16 Placebo 
Seasonal 
rhinoconjuncti
vitis with or 
not 
intermittentor 
mild persistent 
asthmas since 
at least two 
years 
Active vs Placebo: 
• 20 patients out of the 33 enrolled (60.6%) completed the study (13 Active/ 7 
Placebo) 
• Statistically significant decrease of symptom scores (conjunctivitis p<0.02, 
rhinorrea p<0.03 and sneezing p< 0.03) 
• Statistically significant decrease of nasal reactivity at the second year of 
treatment ( p<0.03) 
• Lower consumption of inhaled steroids, mean monthly scores (P < 0.02) 
• Treatment well tolerated; 2 mild local adverse events occurred without 
interruption of therapy 
Burastero, 
S.E (2008) 
[26] 
Efficacy Open, 
observational pilot 
study 
Continuative  
– 60 days - dose of 
2,000 AU once a day 
11 Rhinoconjuncti
vitis with or 
not mild 
asthma for at 
least 2 years 
• Decrease in Allergen-Specific Proliferation to the rPhl p 1 and to the raw grass 
extract after 2 Months of SLIT (P= .002 and .04) 
• Increase in Transcription of IL-10 (P < .001) and TGF-β (P = .06), at rPhl p1–
Stimulated Lymphocytes  
• Correlation indexes of pre-treatment and post-treatment changes in IL-10 vs 
TGF-β expression were 0.17 (P  .47) and 0.16 (P  .70), respective 
Lais 
Parietaria- 
Chemically 
modified 
allergen 
extract of 
parietaria 
pollens 
Ariano R 
(1998) [44] 
Efficacy 
and safety  
 
Randomised, 
placebo controlled, 
double-blind 
parallel study. 
Continuative – 38 week 
treatment – 
25, 100, 300 
and 1,000 AU, 
maximum three times a 
week. The dosage of 
1,000 AU once a week 
till the end of the study 
15/15  Allergic 
rhinitis 
with or without 
asthma  
 
Active vs Placebo: 
• Improvement of score symptoms and drug consumption with a statistically 
significant difference at the end of the treatment (p<0.01) 
• Comparison of the areas of the skin tests and RAST before and after treatment 
showed no statistically significant difference in the two groups.  
• Comparison of nasal or bronchial provocation test before and after treatment with 
statistically significant difference (p<0.05) 
No side effect observed: one patient of active group discontinued the treatment 
owing to digestive troubles (Active Group – 14 out of 15 completed the study) 
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(Parietaria 
judaica 
50%, 
Parietaria 
officinalis 
50%) 
Lombardi C 
(2001) [31] 
Safety  Observational 
Study 
Continuative  
– 16.3 months -  
increasing doses 25, 
50, 100, 200, 300, 600, 
1000 for 8 weeks every 
other day; maintenance 
dose 2,000 AU once a 
week. 
 
46/- Perennial or 
seasonal 
rhinitis and/or 
mild asthma 
• 17 adverse events corresponding to 7.5% of patients and 0.52 per 1000 doses: 7 
episodes of rhinitis, 3 of oral itching, and 1 of abdominal pain. Two cases of 
urticaria and two of abdominal pain/nause were controlled by a temporary dose-
adjustment, and one case of urticaria and conjunctivitis required oral antihistamines.  
• Medical intervention was needed in six patients only during a 3-year period. 
• No severe systemic side-effect  
• *The events reported as results of Lombardi’s study were observed in 198 
patients receiving different SLIT treatments (69 patients – Mites ;75 patients – 
Grasses; 46 – Parietaria; 4 Birch; 1 Olive; 3 Compositae) 
Arena A 
(2003) [45] 
 
Efficacy 
and 
tolerability 
Prospectic 
Observational 
Study 
Continuative -  
Three Years - 
increasing doses 
25/50/100/300 AU and 
1000 AU for 3 
alternate days. 
Maintenance phase 
most patients received 
2000 AU twice weekly 
24 SLIT / 
11 SIT / 9 
pharmacolo
gical 
therapy  
Rhinitis and/or 
mild 
intermittent or 
persistent 
asthma or 
conjunctivitis  
• 8 patients interrupted the immunotherapy during the study period: 3 SLIT group 
and 5 SIT group 
• The physician’s opinion on efficacy, by symptoms and drug consumption 
reduction, was statistically better in the SLIT group than in the other two groups (p< 
0.0001).  
• The difference between the patient’s degree of satisfaction of treatments was 
statistically significant in favour of SLIT treatments (p< 0.0001). 
* The events reported as results of a study observed in 110 patients receiving 
different treatments (Parietaria, Graminacea, Olea, Dermathopaghoides)  
Lombardi C 
(2004) [46] 
 
Safety Multicenter 
observational 
Study 
Continuative – 18 ± 2 
weeks- 1000 AU 
tablets - count: 
3952/4050 tablet  
18  Allergic 
rhinitis and/or 
asthma at least 
2 years 
• 11 mild side effects were reported in 6 (7%*) patients: 6 oral itching, 2 rhinitis, 2 
nausea, and 1 generalized itching 
• Omitted dose was documented in 11 patients. 
*on a total of 86 patients: 41 received SLIT to mite and 45 to pollens (24 grasses, 18 
Parietaria, 3 Ragweed). 
Gammeri E 
(2005) [20] 
 
Safety and 
the 
tolerability  
Open sequential 
Non controlled 
Continuative – 20 
minutes – every 5 
minutes, of increasing 
doses of SLIT 100 AU, 
300 AU, 600 AU, 1000 
AU, 2000 AU 
34  intermittent/per
sistent rhinitis 
or intermittent/ 
mild persistent 
asthma 
Only 1 patient out of 105* (0.9 %) had a mild local symptom (gastric pyrosis) that 
occurred 30 minutes after the last initial dose and spontaneously disappeared as the 
treatment was continued. 
 
*The study observed 105 patients [Dust (n = 56), Parietaria (n = 34) and Timothy-
grass (n =15)] 
La Grutta S 
(2007) [47] 
 
Efficacy Prospective, open- 
controlled 
randomised 
Continuative – 1 year- 
16 days build-up 
25/100/300/1000 AU 
Maintenance 1000 AU, 
2 times a week for 1 
year 
33 SLIT / 
23 Control 
 
*56 pt 
allergic  to 
House Dust 
mite with 
(n-36) or 
without 
Parietaria 
mild persistent 
asthma with or 
not moderate 
intermittent 
moderate 
rhinitis 
Active vs Control 
• All patients completed the study 
• Greater reduction daily of the mean symptom score (p<0.01) and drug 
consumption (p<0.001) in the SLIT than in the control group. 
• MCh PD20 increased only in the SLIT group(p<0.0005)  
• The reduction of nasal eosinophils was statistically greater (P<0.05) only in the 
SLIT group. 
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D’Anneo RW 
(2008) [48] 
Efficacy 
and safety  
 
Prospective, 
randomized, 
With three parallel 
Groups receiving 
either two different 
dosages of SLIT or 
the standard 
chronic 
Continuative – 6 
months -   
1,000 AU/week - 
3,000 AU/week 
24 (SLIT 
1,000 
AU/week) / 
21 (SLIT 
3,000 
AU/week) / 
21 (drug 
therapy) 
Seasonal 
rhinoconjuncti
vitis and/or 
asthma 
(mild 
intermittent or 
mild persistent) 
• VAS: at the 3rd month: p < 0.05 improvement in group of higher dose vs control; 
after 6 months, VAS in the SLIT groups is statistically better than control (p < 0.05) 
• Reduction in rescue medication consumption between 3 and 6 months (p < 0.05) 
in all 3 groups.  
• Reduction bronchial reactivity in the SLIT groups (p < 0.001).  
• Significant increase of MCh PD20 at the end of the study, in both the patients 
treated with 1,000 AU (p < 0.05) and in those treated with 3,000 AU (p < 0.001) 
• No adverse events were observed, no patient interrupted the study  
Passali D 
(2010) [37] 
 
Safety and 
efficacy  
Prospective, 
open, randomized 
study, with three 
parallel groups and 
control group 
Continuative – 6 
months - 1,000 AU 
(Group A) – 4-day up-
dosing 500/1000/1500 
AU (Group B) - 4-day 
up-dosing 300/600/900 
/1200 AU (Group C) 
Maintenance: 1,000 
AU 5-7 times a week 
4 (Group 
A) /3 
(Group B) / 
2 (Group 
C) / 2 
(Control) 
Rhinitis and 
oculo-rhinitis 
Treated VS Control 
• All patients tolerated all the three dosage very well, no patient interrupted 
• A statistically significant (p < 0.02) reduction of SMSs vs control group 
• Significant (p < 0.01) decrease in nasal reactivity the three SLI T-treated groups, 
while the untreated controls remained unchanged 
• A significant increase in VAS values has been observed in all 3 study groups, in 
comparison to the controls (p < 0.001). 
• During up-dosing 4 slight side-effects in 4 patients, 1 somnolence and 1 
tiredness, and 2 oral itching. No side-effects were recorded during the maintenance 
treatment. 
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